- Home
- BCAT vs TMDX Comparison
BCAT vs TMDX Comparison
Compare BCAT & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAT
- TMDX
- Stock Information
- Founded
- BCAT 2020
- TMDX 1998
- Country
- BCAT United States
- TMDX United States
- Employees
- BCAT N/A
- TMDX N/A
- Industry
- BCAT Finance/Investors Services
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BCAT Finance
- TMDX Health Care
- Exchange
- BCAT Nasdaq
- TMDX Nasdaq
- Market Cap
- BCAT 1.8B
- TMDX 2.1B
- IPO Year
- BCAT N/A
- TMDX 2019
- Fundamental
- Price
- BCAT $15.67
- TMDX $57.20
- Analyst Decision
- BCAT
- TMDX Buy
- Analyst Count
- BCAT 0
- TMDX 11
- Target Price
- BCAT N/A
- TMDX $116.10
- AVG Volume (30 Days)
- BCAT 308.8K
- TMDX 2.6M
- Earning Date
- BCAT 01-01-0001
- TMDX 02-24-2025
- Dividend Yield
- BCAT 9.38%
- TMDX N/A
- EPS Growth
- BCAT N/A
- TMDX N/A
- EPS
- BCAT 1.43
- TMDX 0.94
- Revenue
- BCAT N/A
- TMDX $401,090,000.00
- Revenue This Year
- BCAT N/A
- TMDX $81.61
- Revenue Next Year
- BCAT N/A
- TMDX $22.52
- P/E Ratio
- BCAT $11.41
- TMDX $61.04
- Revenue Growth
- BCAT N/A
- TMDX 109.09
- 52 Week Low
- BCAT $13.67
- TMDX $56.03
- 52 Week High
- BCAT $16.38
- TMDX $177.37
- Technical
- Relative Strength Index (RSI)
- BCAT 51.73
- TMDX 35.74
- Support Level
- BCAT $15.40
- TMDX $58.40
- Resistance Level
- BCAT $15.76
- TMDX $67.80
- Average True Range (ATR)
- BCAT 0.22
- TMDX 4.59
- MACD
- BCAT 0.06
- TMDX -0.27
- Stochastic Oscillator
- BCAT 81.58
- TMDX 4.44
About BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.